Gentian Diagnostics AS (OL:GENT) — Market Cap & Net Worth
Market Cap & Net Worth: Gentian Diagnostics AS (GENT)
Gentian Diagnostics AS (OL:GENT) has a market capitalization of $72.38 Million (Nkr687.84 Million) as of May 3, 2026. Listed on the OL stock exchange, this Norway-based company holds position #20446 globally and #181 in its home market, demonstrating a -0.89% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Gentian Diagnostics AS's stock price Nkr44.60 by its total outstanding shares 15422350 (15.42 Million). Analyse GENT operating cash flow to see how efficiently the company converts income to cash.
Gentian Diagnostics AS Market Cap History: 2016 to 2026
Gentian Diagnostics AS's market capitalization history from 2016 to 2026. Data shows growth from $86.01 Million to $72.38 Million (5.92% CAGR).
Gentian Diagnostics AS Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Gentian Diagnostics AS's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.52x
Gentian Diagnostics AS's market cap is 0.52 times its annual revenue
Latest Price to Earnings (P/E) Ratio
6.90x
Gentian Diagnostics AS's market cap is 6.90 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $86.01 Million | $30.90 Million | -$8.93 Million | 2.78x | N/A |
| 2017 | $66.54 Million | $34.99 Million | -$15.17 Million | 1.90x | N/A |
| 2018 | $87.64 Million | $46.11 Million | -$19.80 Million | 1.90x | N/A |
| 2019 | $101.27 Million | $47.95 Million | -$39.86 Million | 2.11x | N/A |
| 2020 | $88.45 Million | $68.37 Million | -$17.11 Million | 1.29x | N/A |
| 2021 | $116.85 Million | $83.12 Million | -$24.79 Million | 1.41x | N/A |
| 2022 | $66.54 Million | $101.64 Million | -$24.00 Million | 0.65x | N/A |
| 2023 | $67.35 Million | $136.19 Million | -$10.65 Million | 0.49x | N/A |
| 2024 | $63.62 Million | $152.07 Million | $45.29 Million | 0.42x | 1.40x |
| 2025 | $91.53 Million | $176.50 Million | $13.26 Million | 0.52x | 6.90x |
Competitor Companies of GENT by Market Capitalization
Companies near Gentian Diagnostics AS in the global market cap rankings as of May 3, 2026.
Key companies related to Gentian Diagnostics AS by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #141 globally with a market cap of $155.56 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #208 globally with a market cap of $112.79 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #230 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #236 globally with a market cap of $102.56 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #141 | Abbott Laboratories | NYSE:ABT | $155.56 Billion | $89.46 |
| #208 | Stryker Corporation | NYSE:SYK | $112.79 Billion | $294.73 |
| #230 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #236 | Medtronic PLC | NYSE:MDT | $102.56 Billion | $80.00 |
Gentian Diagnostics AS Historical Marketcap From 2016 to 2026
Between 2016 and today, Gentian Diagnostics AS's market cap moved from $86.01 Million to $ 72.38 Million, with a yearly change of 5.92%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Nkr72.38 Million | -20.92% |
| 2025 | Nkr91.53 Million | +43.88% |
| 2024 | Nkr63.62 Million | -5.54% |
| 2023 | Nkr67.35 Million | +1.22% |
| 2022 | Nkr66.54 Million | -43.06% |
| 2021 | Nkr116.85 Million | +32.11% |
| 2020 | Nkr88.45 Million | -12.66% |
| 2019 | Nkr101.27 Million | +15.56% |
| 2018 | Nkr87.64 Million | +31.71% |
| 2017 | Nkr66.54 Million | -22.64% |
| 2016 | Nkr86.01 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Gentian Diagnostics AS was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $72.38 Million USD |
| MoneyControl | $72.38 Million USD |
| MarketWatch | $72.38 Million USD |
| marketcap.company | $72.38 Million USD |
| Reuters | $72.38 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Gentian Diagnostics AS
Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and… Read more